In this episode, Paul Richardson, MD, presents the primary results from the randomized phase 3 DETERMINATION trial, which was started in 2010. Dr Richardson speaks about the active combination of lenalidomide, bortezomib, and dexamethasone(RVd) and autologous stem cell transplantation and R maintenance to progression for patients with newly diagnosed multiple myeloma. Dr Richardson spoke on this topic at 2022 ASCO Annual Meeting in Chicago, Illinois.